REDHILL BIOPHARMA LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.433 USD | +1.17% |
|
-2.12% | -70.34% |
| Sales 2022 | 61.8M 84.88M | Sales 2023 | 6.53M 8.97M | Capitalization | 28.72M 39.45M |
|---|---|---|---|---|---|
| Net income 2022 | -71M -97.51M | Net income 2023 | 23M 31.59M | EV / Sales 2022 | 1.87 x |
| Net Debt 2022 | 103M 141M | Net cash position 2023 | 4.4M 6.04M | EV / Sales 2023 | 3.73 x |
| P/E ratio 2022 |
-0.12
x | P/E ratio 2023 |
0.4
x | Employees | 53 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 99% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
| 1 day | +1.17% | ||
| 1 week | -2.12% | ||
| Current month | -18.29% | ||
| 1 month | -18.29% | ||
| 3 months | -32.70% | ||
| 6 months | -8.44% | ||
| Current year | -70.34% |
1 week
0.40
0.44
1 month
0.300.56
Current year
0.301.54
1 year
0.263.28
3 years
0.26447.20
5 years
0.26460.80
10 years
0.26888.80
| Managers | Title | Age | Since |
|---|---|---|---|
Dror Ben-Asher
CEO | Chief Executive Officer | 59 | 09-08-02 |
Ori Shilo
FOU | Founder | 57 | 09-08-02 |
Razi Ingber
DFI | Director of Finance/CFO | - | 23-01-04 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Rick Scruggs
BRD | Director/Board Member | 64 | 15-12-31 |
Shmuel Cabilly
BRD | Director/Board Member | 74 | 10-08-25 |
| Director/Board Member | 80 | 10-05-02 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-29 | 0.433 | +1.17% | 381,285 |
| 24-04-26 | 0.428 | +2.82% | 220,476 |
| 24-04-25 | 0.4162 | -0.87% | 272,698 |
| 24-04-24 | 0.4199 | -1.84% | 193,132 |
| 24-04-23 | 0.4278 | -3.30% | 473,109 |
Delayed Quote Nasdaq, April 29, 2024 at 04:30 pm
More quotes
RedHill Biopharma Ltd is an Israel-based specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs such as, Talicia for the treatment of Helicobacter pylori (H. pylori) infection, and Aemcolo, for the treatment of travelersâ diarrhea. RedHillâs clinical late-stage development programs include: :info: RHB-204, for pulmonary nontuberculous mycobacteria (NTM) disease; opaganib (ABC294640), host-directed, SPHK2 inhibitor targeting multiple indications, RHB-107 (upamostat), an oral, host-directed serine protease inhibitor with potential for pandemic preparedness, is in late-stage development for treatment of non-hospitalized symptomatic COVID-19, and is targeting multiple other cancer and inflammatory gastrointestinal diseases; RHB-104 for Crohn's disease; and RHB-102 for chemotherapy and radiotherapy induced nausea and vomiting.
Sector
Pharmaceuticals
Calendar
2024-05-06
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -70.34% | 13.8M | |
| -3.45% | 87.17B | |
| +1.97% | 40.1B | |
| -16.72% | 31.38B | |
| +57.48% | 25.12B | |
| -14.82% | 15.59B | |
| -8.82% | 12B | |
| -41.58% | 11.8B | |
| -16.29% | 11.8B | |
| +6.89% | 8.81B |
- Stock Market
- Equities
- RDHL Stock
